Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

@article{Kumar2012RandomizedMP,
  title={Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.},
  author={Shaji K Kumar and I. Flinn and Paul G Richardson and Parameswaran N. Hari and Natalie Scott Callander and Stephen J. Noga and Alexander Stewart and Francesco Turturro and Robert Rifkin and Jeffrey Wolf and Jose Estevam and George J. Mulligan and Hongliang Shi and Iain James Webb and S Vincent Rajkumar},
  journal={Blood},
  year={2012},
  volume={119 19},
  pages={4375-82}
}
Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This randomized phase 2 trial evaluated VDC, VDR, and VDCR in previously untreated multiple myeloma (MM). Patients received V 1.3 mg/m2 (days 1, 4, 8, 11) and D 40 mg (days 1, 8, 15), with either C 500 mg/m2 (days 1, 8) and R 15 mg (days 1-14; VDCR), R 25 mg (days 1-14; VDR), C 500 mg/m2 (days 1, 8; VDC) or C 500 mg/m2 (days 1, 8, 15; VDC-mod) in 3-week… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 36 times over the past 90 days. VIEW TWEETS
114 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 114 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…